Complex evaluation of human monocyte‐derived dendritic cells for cancer immunotherapy

• Published in: Journal of cellular and molecular medicine Vol. 16; no. 11; pp. 2827 - 2837
• Main Authors: Vopenkova, Katerina, Mollova, Klara, Buresova, Ivana, Michalek, Jaroslav
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.11.2012; BlackWell Publishing Ltd
• Subjects: Biomarkers - metabolism; cancer immunotherapy; Cell Line, Tumor; Cell Movement; Cells, Cultured; Cytokines - metabolism; cytotoxicity; dendritic cell; Dendritic Cells - immunology; Granulocyte-Macrophage Colony-Stimulating Factor - metabolism; Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology; Humans; Immunotherapy - methods; Interleukin-10 - metabolism; Interleukin-12 - metabolism; Interleukin-4 - metabolism; Interleukin-4 - pharmacology; interleukin‐12; maturation; migration; Monocytes - cytology; Neoplasms - immunology; Neoplasms - therapy; Original; T-Lymphocytes - immunology
• ISSN: 1582-1838; 1582-4934; 1582-4934
• DOI: 10.1111/j.1582-4934.2012.01614.x

Dendritic cell (DC) immunotherapy is capable of generating tumour‐specific immune responses. Different maturation strategies were previously tested to obtain DC capable of anti‐cancer responses in vitro, usually with limited clinical benefit. Mutual comparison of currently used maturation strategies and subsequent complex evaluation of DC functions and their stimulatory capacity on T cells was performed in this study to optimize the DC vaccination strategy for further clinical application. DC were generated from monocytes using granulocyte–macrophage colony‐stimulating factor (GM‐CSF) and interleukin (IL)‐4, pulsed with whole tumour cell lysate and then matured with one of five selected maturation strategies or cultured without additional maturation stimulus. DC were characterized with regard to their surface marker expression, cytokine profiles, migratory capacity, allogeneic and autologous T cell stimulatory capacity as well as their specific cytotoxicity against tumour antigens. We were able to demonstrate extensive variability among different maturation strategies currently used in DC immunotherapeutic protocols that may at least partially explain limited clinical benefit of some clinical trials with such DC. We identified DC matured with interferon‐γ and lipopolysaccharide as the most attractive candidate for future clinical trials in cancer immunotherapy.